deferoxamine has been researched along with linezolid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ | 1 |
1 review(s) available for deferoxamine and linezolid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for deferoxamine and linezolid
| Article | Year |
|---|---|
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG.
Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide | 2021 |